-
2022-03-21
Nuance Pharma Announces License and Supply Agreement with Bavarian Nordic on the Development and Commercialization of Respiratory Syncytial Virus (RSV) Vaccine for Adults in China and Selected Asian Markets
SHANGHAI, March 21, 2022 /PRNewswire/ -- Nuance Pharma ("the Company") announced today, that it has entered into an exclusive license and supply agreement with Bavarian Nordic, a Copenhagen-based fully integrated vaccines company focused on the
-
2022-03-04
Altamira Therapeutics and Nuance Pharma Enter Into Exclusive Licensing and Distribution Agreement for Bentrio in China and Additional Asian Markets
HAMILTON, BERMUDA / ACCESSWIRE / March 4, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, announced today
-
2022-01-06
Nuance Pharma acquires Sino Health to further strengthen its commercial capabilities and expand pipelines
SHANGHAI, Jan. 6, 2022 /PRNewswire/ -- Nuance Pharma ("Nuance"or the "Company"), a specialty care focused biopharma with late late-stage clinical programs and existing commercial operations, today announced an agreement with Sino Healt
Contact PR
